Early life antibiotic use and the risk of asthma and asthma exacerbations in children by Ahmadizar, Fariba et al.
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/pai.12725 
This article is protected by copyright. All rights reserved. 
DR. STEVE  TURNER (Orcid ID : 0000-0001-8393-5060) 
MS. EVELIEN R VAN MEEL (Orcid ID : 0000-0002-0826-9931) 
PROF. ANKE-HILSE  MAITLAND (Orcid ID : 0000-0002-0414-3442) 
 
Article type      : Original 
 
Early life antibiotic use and the risk of asthma and asthma exacerbations in children  
 
Fariba Ahmadizar1, Susanne J. H. Vijverberg1,2, Hubertus G. M. Arets3, Anthonius de Boer1, Steve 
Turner4, Graham Devereux4, Ali Arabkhazaeli1, Patricia Soares5, Somnath Mukhopadhyay 5,6, Johan 
Garssen7,8, Colin N.A. Palmer9, Johan C. de Jongste10, Vincent WV Jaddoe 11 ,Liesbeth Duijts10,11,12, 
Evelien R. van Meel10,11, Aletta D. Kraneveld7,13, Anke H. Maitland-van der Zee1,2* 
 
Affiliation: 
1) Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for 
Pharmaceutical Sciences (UIPS), Faculty of science, Utrecht University, Utrecht, the Netherlands 
2)    Department of Respiratory Medicine, Academic Medical Centre, University of Amsterdam,    
Amsterdam, the Netherlands 
3) Department of Pediatric Pulmonology and Allergology, Department of Pediatrics, University 
Medical Centre Utrecht, Utrecht, The Netherlands 
4) Child Health, Royal Aberdeen Children’s Hospital, Aberdeen, UK  
5) Academic Department of Pediatrics, Brighton & Sussex Medical School, Royal  Alexandra  
        Children's Hospital, Brighton, United Kingdom 
6) Population Pharmacogenetics Group, Biomedical Research Institute, University of Dundee, 
Ninewells Hospital and Medical School, Dundee 
7) Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of 
science, Utrecht University, Utrecht, the Netherlands 
8) Nutricia Research, Utrecht, the Netherlands 
9) Population Pharmacogenetics Group, Biomedical Research Centre, University of Dundee, 
Dundee UK 
10) Department of Pediatrics, Division of Respiratory Medicine and Allergology, Erasmus MC, 
University Medical Center, Rotterdam, The Netherlands 
11) Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, The 
Netherlands 
12) Department of Pediatrics, Division of Neonatology, Erasmus MC, University Medical Center, 
Rotterdam, The Netherlands 
13) Institute for Risk Assessment Sciences, Faculty of Veterinary Medicine, Utrecht University, 
Utrecht, the Netherlands 
 
Running title: Antibiotic and risk of asthma/asthma exacerbations in children 
 
*Corresponding authors: 
Department of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, 
Amsterdam, the Netherlands. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
E-mail: a.h.maitland@amc.uva.nl 
Post address: Department of Respiratory Disease, F5-259, P.O. Box 22660, The Netherlands 
Tel: +31 (20) 5668137 
Fax: (+31) (0)30-2539166 
 
Word count: 2,667 
Number of tables: 4 
Number of figures: 2 
 
Sources of support: No funding source had any role in the design and conduct of the study, the 
collection, management, analysis and interpretation of the data or the preparation, review or approval 
of the manuscript. 
 
Ahmadizar. F, Vijverberg. S, Arets. H, de Boer. A, Turner. S, Devereux. G, Arabkhazaeli. A, Soares. 
P, Mukhopadhyay. S, Garssen. J, Palmer. C, de Jongste. J, Jaddoe. V, Duijts. L, van Meel. E, 
Kraneveld. A, Maitland-van der Zee. A 
Early life antibiotic use and the risk of asthma and asthma exacerbations in children  
 
PAI journal 
 
Abstract 
Background.  The use of antibiotic therapy early in life might influence the risk of 
developing asthma. Studies assessing the influence of early life antibiotic use on the risk of 
asthma exacerbations are limited, and the results are inconsistent. Therefore, the aim of this 
study was to assess the association between use of antibiotic during the first three years of life 
and the risk of developing childhood asthma and the occurrence of asthma exacerbations. 
Methods. Data from four large childhood cohorts were used; two population-based cohorts to 
study the risk of developing asthma: Generation R (n=7,393, the Netherlands) and SEATON 
(n=891, Scotland, UK), and two asthma cohorts to assess the risk of asthma exacerbations: 
PACMAN (n=668, the Netherlands) and BREATHE (n=806, Scotland, UK). Odds ratios 
(ORs) were derived from logistic regression analysis within each database followed by 
pooling the results using a fixed- or random-effect model. 
Results. Antibiotic use in early life was associated with an increased risk of asthma in a 
meta-analysis of the Generation R and SEATON data (OR: 2.18, 95% CI: 1.04-4.60; I2: 
76.3%). There was no association between antibiotic use in early life and risk of asthma 
exacerbations later in life in a meta-analysis of the PACMAN and BREATHE data (OR: 
0.93, 95% CI: 0.65-1.32; I2: 0.0%). 
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Conclusion. Children treated with antibiotic in the first three years of life are more likely to 
develop asthma, but there is no evidence that the exposure to antibiotic is associated with 
increased risk of asthma exacerbations. 
Key words: Antibiotic, asthma, asthma exacerbations, early life, pediatrics. 
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Introduction 
Several environmental and genetic factors have been identified as risk factors for asthma and 
asthma exacerbations (1-4), including early life risk factors such as antibiotic exposure. 
However, previous studies have shown conflicting findings whether antibiotic exposure in 
early life increases the risk of asthma development in children. Furthermore, the association 
between early life antibiotic use and severity of asthma is not well studied (5).  
The aim of this study was to evaluate the effect of early life antibiotic use on the risk of 
asthma onset later in life in the general population. Moreover, in the pediatric population with 
asthma, the association between early life antibiotic use and risk of asthma exacerbations 
later in life was studied. 
 
Methods 
Study setting and population. To study the effect of antibiotic treatment early in life on 
asthma development, we used data from two population-based cohorts (Generation R (6) and 
SEATON (7, 8)), and to assess the effect of early life antibiotic use on asthma exacerbations 
we used data from two pediatric asthma populations (PACMAN (9) and BREATHE (10, 
11)). Generation R is a Dutch prospective population-based cohort study (n=7,393) of 
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children from fetal life until young adulthood. Detailed information on the design and 
methods of this study has been described previously (6). SEATON is a Scottish birth cohort 
study (n=2,000). Between 1997 and 1999, healthy unselected pregnant women attending an 
antenatal clinic, at median 11 weeks gestation, were recruited. In this study, singletons born 
to the recruited women were followed up for 10 years (7, 8).  PACMAN (n=995), is a Dutch 
cohort of 4-12 year olds on asthma medication, selected through Dutch community 
pharmacies. In this cohort, children with at least two years of dispensed medication data 
available and at least three prescriptions for any asthma drug within the last two years and at 
least one prescription in the last six months were selected from pharmacies in the Netherlands 
(9). BREATHE is a Scottish cohort of children aged 3-19 years (n=1,100) with physician-
diagnosed asthma recruited through primary or secondary clinics. The Community Health 
Index (CHI) coding was available for the BREATHE participants and data could be linked to 
several other databases e.g. community prescribing information and diagnosis of acute 
hospital admission (10, 11). Within the four cohorts questionnaire-based information was 
available on general health, allergic symptoms, asthma and respiratory symptoms, healthcare 
utilization for respiratory symptoms, environmental and socio demographic factors. 
Exposure. Antibiotic use in the Generation R cohort (first three years) and in the SEATON 
cohort (first six months) was available from parental-reported data. In PACMAN and 
BREATHE, pharmacy data were available from the 1st year of life, including detailed 
information on dispensed medication. In PACMAN, ATC codes (listed in Table S1) and in 
BREATHE, British National Formulary (BNF) codes (including all antibiotic in Chapter 5.1 
of the BNF (12)) were used. Date of dispensing, duration, and amount dispensed and doses 
were extracted from these databases. In case of missing values, duration of antibiotic was 
calculated by assuming a course of 7 days. Depending on the available information in the 
four databases, antibiotic use was classified as 1) exposed vs. never exposed (in all four 
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databases), 2) the timing of the first antibiotic use:  1st year, the 2nd year or the 3rd year of life 
(in Generation R, PACMAN and  BREATHE), 3)  the number of prescriptions for antibiotic 
during the first three years (PACMAN and BREATHE), and 4) the total days of exposure to 
antibiotic during the first three years (PACMAN and BREATHE).  
 
Outcomes. Two outcomes were defined in this study: 1) physician-diagnosed asthma, 
defined as a positive response to the following questions at age of 9-10 years in Generation R 
and at age of 10 years in SEATON “has your child ever suffered from asthma?” and “was 
this confirmed by a doctor?”, and 2) asthma exacerbations, defined as asthma-related visits to 
an emergency department (ED) and/or the use of oral corticosteroids (OCS) in the past 12 
months in PACMAN and asthma-related hospitalization and/or OCS use in the past 6 months 
in BREATHE(13). Since data on asthma control (measured with asthma control questionnaire 
(ACQ) were only available in PACMAN database, we were not able to study this outcome. 
Statistical analysis. Children with missing values on exposure and outcomes were excluded 
from data analyses. The baseline characteristics of children with and without missing data 
were compared. Univariate and multivariable logistic regression analyses were used to 
estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between 
exposure and outcomes. Based on available variables in each database, the associations were 
adjusted for different confounders. In Generation R, the potential confounders were age, 
gender, and family history of asthma/allergy and in SEATON, gender, and family history of 
asthma. In PACMAN and BREATHE, age, gender and family history of asthma/allergy were 
included in the model. In PACMAN and BREATHE, we tested the association of number of 
courses and duration of antibiotic with asthma exacerbations. In subgroup analyses, the effect 
of age on this association was also tested in stratified analyses in three different age 
categories >4 and ≤6,  >6. and ≤13 years in PACMAN and >3 and ≤6, >6 and ≤13 and >13. 
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and ≤19 years in BREATH. In all analyses children exposed to antibiotic were compared 
with unexposed children. The estimates for the association between antibiotic use and asthma 
in the Generation R and SEATON cohorts were meta-analyzed using a fixed-or random-
effect model. In the Generation R cohort, we only used the 1st year of life of antibiotic 
exposure for better comparability with the SEATON cohort in which the exposure to 
antibiotic was only known for the first six months. A similar meta-analysis was performed for 
the association between antibiotic use and asthma exacerbations in PACMAN and 
BREATHE. All statistical analyses were conducted using statistical package R version 3.2.3 
(14), SPSS version 21 and STATA 14/SE (15). 
 
Results 
In the population-based cohorts, 7,393 children in Generation R and 891 out of 2,000 
children in SEATON had data available on both exposure to antibiotic and respiratory 
outcome. In Generation R, the rate of early life exposure to antibiotic (1st year) was 55% 
while in SEATON, this rate (first 6 months) was 29% (Table 1). Cumulative incidence rates 
of asthma in Generation R and SEATON were 10% and 8%, respectively. In the asthma 
populations, 668 out of 995 (PACMAN) and 806 out of 1,100 (BREATHE) children had 
pharmacy data available starting from the 1st year and were therefore included in this study. 
In these two databases, 78 and 84% of children had at least one antibiotic prescription during 
the first three years, respectively. The rate of children with at least one asthma exacerbation 
varied between 12% in PACMAN and 24% in BREATHE.  
In the SEATON cohort, there were no statistically significant differences in baseline 
characteristics of children with and without missing data on early life antibiotic use except for 
family history of asthma (Table S2). When we compared the baseline characteristics of 
children who were lost to follow-up (unknown asthma diagnosis) with those included in the 
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analyses, the results showed statistically significant difference in gender and family history of 
asthma between the two groups but not in exposure to antibiotics in early childhood (data not 
shown). 
Early life antibiotic use and asthma susceptibility. In the two population-based cohorts, 
pooled results showed that children who used antibiotic during the 1st year of life were 
statically significantly more likely to develop asthma (summary OR: 2.18, 95% CI: 1.04-
4.60; I2: 76.3%) compared with those without antibiotic (Fig 1). In Generation R, antibiotic 
consumption in the 1st year of life was associated with a higher risk of developing asthma 
(adjusted OR (aOR): 3.21, 95% CI: 1.89-5.45) compared with antibiotic use in the 2nd year of 
life (aOR: 2.25, 95% CI: 1.18-4.30) or in the 3rd year of life (aOR: 2.21, 95% CI: 0.92-5.33). 
In SEATON, antibiotic use during the first six months of life was not significantly associated 
with an increased risk of asthma (aOR: 1.50, 95% CI: 0.91-2.46) (Table 2). 
Early life antibiotic use and asthma exacerbations. In the two asthma populations, pooled 
results showed no associations between early life antibiotic use and asthma exacerbations 
(summary OR: 0.93, 95% CI: 0.65-1.32; I2: 0.0%) (Fig 2). No statistically significant 
differences between different timing of antibiotic use (first, second or third year of life) and 
the risk of asthma exacerbations were observed in PACMAN and BREATHE. In both 
studies, there were no significant associations between the number or duration of antibiotic 
courses and the risk of asthma exacerbations later in life (Table 3). 
The results of age-stratified logistic regression analyses showed no statistically significant 
differences between different age categories in the two asthma populations. However, in both 
studies there seemed to be a trend towards a higher risk of asthma exacerbations in younger 
(4-6 years in PACMAN and 3-6 years in BREATHE) compared to older children (Table 4). 
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Discussion 
In this study, we showed children who had been exposed to antibiotic early in life had a 
higher risk of developing asthma. However, asthmatic children who were exposed to 
antibiotic early in life did not have a higher risk of asthma exacerbations.  
In recent decades, a rise in the proportion of children treated with antibiotic in early 
childhood has been reported; the highest rate of antibiotic use (18.7%) was shown in children 
aged >1 month to 18 years treated for a bacterial lower respiratory tract infection (16). Due to 
a high burden of infections in children in the first years of life the prescribing rate of 
antibiotic is high (in our study around 80%). When antibiotic use in early life indeed 
increases the risk of asthma, it would be important to be more critical about the prescription 
of antibiotic. Studies have shown that antibiotics are often prescribed inappropriately (17, 18) 
for indications for which antibiotics are not necessary like common cold and sinusitis caused 
by viral infections. 
 
Our findings regarding a higher risk of asthma in children exposed to antibiotic at an early 
age are in line with previous studies (19-23). In a very recent population-based birth cohort 
study of 143,000 children, a high risk of new-onset asthma was observed in children treated 
with antibiotic before the age of 12 months (incidence rate ratio: 1.51) (20). In the Generation 
R cohort, we showed that the strongest risk of asthma was in children exposed to antibiotic 
during the first year of life and the effect decreased if they were treated at an older age. 
Previous studies showed that the risk of asthma in children exposed to antibiotic in early life 
diminished with aging, and was no longer statistically significant after three years of age (24, 
25). Our findings were also in line with the findings of a meta-analysis including 18 studies 
that reported a weak but statistically significant association between early life antibiotic 
exposure and the development of asthma (OR: 1.27, 95% CI: 1.12-1.43) (19).  
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A higher risk of asthma among children treated with antibiotic during early childhood could 
be explained in different ways. First, the immunomodulatory effect of antibiotic in which 
changes in the intestinal bacterial diversity during the first months of life influence the 
immune system, T helper and regulatory T cell (Tregs) balance. Evidence showed that 
modifiable factors such as gut microbiome and diet have a key role in the maturation of the 
neonatal immune system and thereby might also affect the risk of asthma and asthma 
exacerbations (1, 26, 27). The healthy gut microbiome is highly diverse and can be disturbed 
by environmental factors e.g. antibiotic therapy.  
Another explanation for the higher risk could be confounding by indication. It is possible that 
children who are in need of antibiotic early in life, have already a Th1/Th2 imbalance caused 
by the infections treated with the antibiotic and that this makes them more susceptible for 
asthma later in life. In the Generation R and SEATON cohorts, we cannot rule out that 
respiratory symptoms in early life treated with antibiotic might have been the first signs of 
asthma.  
Prevalence rate of asthma exacerbations varied widely between PACMAN (12%) and 
BREATHE (24%) studies; children in the BREATHE study have approximately twice the 
risk of asthma exacerbations. Importantly, children in the PACMAN study were recruited 
through community pharmacies based on their regular use of medication for asthma 
treatment, while participants of the BREATHE were recruited through primary and secondary 
asthma clinics. Therefore, the children included in BREATHE might reflect a more severe 
asthma population who more often suffer from asthma exacerbations. Cultural differences in 
OCS prescriptions in different countries might also explain part of the discrepant results. 
However, the results of the association between antibiotic and asthma exacerbations were 
very similar in PACMAN and BREATHE; even though the point estimates were in opposite 
directions the 95% CIs largely overlapped. A previous study reported a statistically 
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significant positive association between antibiotic use and asthma exacerbations shortly after 
treatment with antibiotic (before the age two years), and not at older age (5). The latter 
finding is in line with the findings in our study, however, we did not have data to study 
asthma exacerbations before the age of two years. 
There are some potential limitations in this study that should be acknowledged. Importantly, 
our study was limited by the high rate of missing data in the three studies including SEATON 
(56%), PACMAN (33%) and BREATHE (27%). When assessing the baseline characteristics 
of the children with and without missing data, in SEATON cohort the results showed no 
statistically significant differences in asthma development between children with and without 
missing data on antibiotic use in early childhood. Therefore, our study was not prone to 
selection bias. However, the results of analyses in the two asthma populations showed 
statistically significant differences in asthma exacerbations between the two groups in which 
those who had missing data on early life medications had remarkably less asthma 
exacerbations compared with those with available data in PACMAN (6.1% vs 12.3%, 
p=0.003) and in BREATHE (11.6% vs 24.3%, p=0.01). Therefore, this might have led to an 
overrepresentation of children with more severe asthma in the analyses.  
Another important limitation in this study was the heterogeneity in study designs. For 
example in Generation R antibiotic use in the first three years of life were assessed, while the 
first six months of life were assessed in SEATON. Different time periods for antibiotics 
exposure (and therefore different age at time of antibiotic consumption) might have led to a 
stronger association in Generation R compared with SEATON study. In the asthma studies 
antibiotic exposure could be defined based on pharmacy data, while these data were not 
available in the population based studies. In these studies, the use of antibiotic was parental 
reported, this definition might be more prone to recall bias. 
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The definition of asthma diagnosis in both SEATON and Generation R was based on a 
parental questionnaire. This might have led to misclassification of asthmatic children 
especially when the diagnosis was obtained at a young age or an under-reporting of asthma 
cases. However, we previously showed that there is a high agreement (89%) between 
physician-diagnosis asthma and parental-reported asthma in the PACMAN study (28). 
 
Heterogeneity in confounders involved in the adjusted models is another limitation. The 
associations in different populations were adjusted for different confounders based on 
available variables in each study. Lack of consistent adjustment in the present study might 
have influenced the associations; the possibility remains that some factors which were not 
measured in every population caused confounding. 
The present study was also limited by the lack of availability of potential confounders such as 
genetic factors, socioeconomic status and infections/siblings. In none of the databases, we 
had information about the indications for the prescribing of antibiotic.  
In summary, our findings show a higher risk of asthma in children who are treated with 
antibiotic early in life, but no association of early life antibiotic use and asthma exacerbations 
later in asthmatic children. We propose that further research is needed to explore the effects 
of antibiotic on the immune system and gut microbiome in the pathogenesis of asthma.  
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Table 1. Characteristics of the Generation R, SEATON, PACMAN and BREATHE studies 
  Generation R SEATON PACMAN BREATHE 
  N=7,393 N=891 N=668 N=806 
Gender (boys), n (%)  3,707 (51.1) 421 (47.3) 423 (63.3) 508 (63.0) 
Age, mean (SD)  NA NA 8.04 (2.4) 9.5 (3.6) 
Age categories 3.0-6.0 years* NA NA 166 (24.9) 213 (26.4) 
 
6.01-13.0 years NA NA 502 (75.1) 492 (61.0) 
 
13.01-19.0 years NA NA NA 101 (12.5) 
Early life antibiotic exposure, n (%) Exposed 3,178 (80.3) 260 (29.2) 523 (78.3) 680 (84.4) 
 Non-exposed 782 (19.7) 631 (70.8) 145 (21.7) 126 (15.6) 
The timing of the first antibiotic use, n 
(%) 
1st year of life 1,820 (55.2) 260 (29.2) 316 (60.4) 350 (51.5) 
 2nd year of life 503 (15.3) NA 145 (27.7) 201 (29.5) 
 3rd year of life 191 (5.8) NA 62 (11.8) 129 (19.0) 
Frequency of antibiotic prescriptions in 
the first three years, n (%) 
1 NA NA 131 (25.1) 142 (20.8) 
 2 NA NA 102 (19.5) 111 (16.4) 
 ≥3 NA NA 290 (55.5) 427 (62.8) 
Duration of antibiotic used during the 
first three years, n (%) 
≤10 days NA NA 121 (23.1) 142 (20.8) 
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 11-30 days NA NA 225 (43.0) 270 (39.7) 
 >31 days NA NA 176 (33.7) 268 (39.4) 
Asthma diagnosis, n (%)  448 (9.5) 74 (8.3) NA NA 
Exacerbations**, n (%)  NA NA 82 (12.3) 196 (24.3) 
Family history of asthma***, n (%)  664 (16.7) 218 (24.5) 305 (47.5) 315 (39.8) 
Family history of allergy/atopy****, n 
(%) 
 2,739 (60.5) NA 524 (81.0) 351 (44.4) 
Abbreviations: SD, standard deviation; NA, not available 
Early life antibiotic use in Generation R (first three years) and SEATON (first six months) is based on parental-reported data. 
Prescribing data for the 1st years of life was available in PACMAN and BREATHE. 
*This age category is 4-6 years in the PACMAN study.  
**Asthma exacerbations defined as at least one course oral corticosteroids use and/or at least one emergency department visits/hospitalizations due to asthma 
***At least one asthmatic parent 
****At least one allergic/atopic parent 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
 
Fig 1. Pooled odds ratio of the association between early life exposure to antibiotic and asthma development, 
using random-effect model  
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Table 2. Associations between early life exposure to antibiotic and asthma development 
 Crude OR (95% CI) *Adjusted OR (95% CI) 
Generation R 
Ever exposed vs. never exposed to antibiotic, 
n=7,393 
  
Ever exposed, n=3,178 3.29 (2.17-5.00) 2.84 (1.70-4.75) 
Never exposed, n=782 Reference 
1st year of life antibiotic use, n=1,820 3.68 (2.40-5.65) 3.21 (1.89-5.45) 
2nd year of life antibiotic use, n=503 2.70 (1.61-4.54) 2.25 (1.18-4.30) 
3rd year of life antibiotic use, n=191 2.63 (1.35-5.11) 2.21 (0.92-5.33) 
SEATON 
Ever exposed vs. never exposed to antibiotic, 
n=891 
  
Ever exposed, n=260 1.54 (0.94-2.52) 1.50 (0.91-2.46) 
Never exposed, n=631 Reference 
Abbreviations: OR, odds ratio; CI, confidence interval 
Reference is never exposed group in all analyses. 
Bold numbers: statistically significant associations. 
*Adjusted for age, gender, and family history of asthma/allergy in Generation R, and for gender, and family 
history of asthma in SEATON, using multivariable logistic regression analysis. 
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Table 3. Associations between early life exposure to antibiotic and asthma exacerbations 
  Crude OR (95% CI) *Adjusted OR (95% CI) 
PACMAN 
Ever exposed vs. never exposed to 
antibiotic, n=668    
Ever exposed, n=523  1.16 (0.65-2.08) 1.09 (0.60-1.96) 
Never exposed, n=145  Reference 
Frequency of antibiotic 
use**,n=668 
1 antibiotic, n=131 0.74 (0.33-1.66) 0.68 (0.30-1.56) 
2 antibiotics, n=102 1.39 (0.65-2.96) 1.19 (0.54-2.61) 
≥3 antibiotics, n=290 1.29 (0.70-2.39) 1.25 (0.67-2.34) 
Cumulative duration of antibiotic 
use, n=667 
≤ 10 days n=121 0.81 (0.36-1.81) 0.67 (0.28-1.58) 
11-30 days n=225 1.01 (0.52-1.96) 0.95 (0.48-1.87) 
≥30 days n=176 1.66 (0.86-3.18) 1.61 (0.83-3.13) 
BREATHE 
Ever exposed vs. never exposed to 
antibiotic, n=806    
Ever exposed, n=680  0.81 (0.53-1.24) 0.85 (0.55-1.32) 
Never exposed, n=126  Reference 
Frequency of antibiotic use**, 
n=680 
1 antibiotic, n=142 0.88 (0.51-1.52) 0.99 (0.57-1.71) 
2 antibiotics, n=111 0.72 (0.40-1.30) 0.78 (0.42-1.44) 
≥3 antibiotics, n=427 0.81 (0.51-1.26) 0.82 (0.52-1.31) 
Cumulative duration of antibiotic 
use, n=680 
≤ 10 days, n=142 0.88 (0.51-1.52) 0.99 (0.57-1.71) 
11-30 days, n=270 0.82 (0.51-1.33) 0.87 (0.53-1.43) 
≥30 days, n=268 0.75 (0.46-1.22) 0.76 (0.46-1.25) 
Abbreviations: OR, odds ratio; CI, confidence interval 
Reference is never exposed group in all analyses. 
*Adjusted for age, gender and family history of asthma/allergy, using multivariable logistic regression analysis. 
** Number of courses of antibiotic 
Asthma exacerbations defined as at least one course oral corticosteroids use and/or at least one emergency 
department visits/hospitalizations due to asthma; 
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Fig 2. Pooled odds ratio of the associations between early life exposure to antibiotics and asthma exacerbations, 
using fixed-effect model 
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Table 4: Associations between early life antibiotic use and asthma exacerbations, stratified by age 
 Crude OR (95% CI) *Adjusted OR (95% CI) 
PACMAN 
Ever exposed vs. never exposed to antibiotic   
>4 and ≤6 years, n=166   
Ever exposed, n=139 1.84 (0.52-6.58) 1.82 (0.49-6.74) 
Never exposed, n=27 Reference 
>6. and ≤13 years, n=502   
Ever exposed, n=384 0.94 (0.48-1.82) 0.56 (0.30-1.04) 
Never exposed, n=118 Reference 
BREATHE 
Ever exposed vs. never exposed to antibiotic, 
n=806 
  
>3 and ≤6 years, n=213   
Ever exposed, n=183 1.08 (0.47-2.51) 1.19 (0.50-2.83) 
Never exposed, n=30 Reference 
>6. and ≤13 years, n=492   
Ever exposed, n=420 0.65 (0.37-1.12) 0.70 (0.38-1.24) 
Never exposed, n=72 Reference 
>13. and ≤19 years, n=101   
Ever exposed, n=27 0.75 (0.21-2.64) 0.75 (0.21-2.64) 
Never exposed, n=24 Reference 
Abbreviations: OR, odds ratio; CI, confidence interval 
*Adjusted for gender and family history of asthma/allergy;  
Asthma exacerbations defined as at least one course oral corticosteroids use and/or at least one emergency 
department visits/hospitalizations due to asthma.  
 
